Dutch-based Matisse Pharmaceuticals Raises €3.6M in fresh funding with existing and new shareholders. Matisse received the funding from Brightlands Venture Partners, private investment companies, informal investors and the management team.
The fresh new funding will allow Matisse to effectively continue its preparation for a large scale phase II study in sepsis patients. In the course of 2024, Matisse aims to conclude a series A funding round which should cover the full execution of the mentioned phase II clinical trial, the scale up of production to a commercial scale level and to progress on a number of R&D projects, thereby also further strengthening the organization.
Matisse will shortly be able to announce the results of the phase 1/2a Histoseps trial in sepsis patients, which is a major milestone for the company.
Marcel Jacobs, CEO of Matisse Pharmaceuticals said, “We are thankful for the confidence of our existing and new investors in our company and developments. Being able to close this round just before a major milestone publication and in a difficult 2023 biotech funding environment, underpins the support for and importance of finding a solution for treating sepsis”,.
About Matisse Pharmaceuticals
Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock.